A database of FDA approved therapeutic peptides and proteins
ID | ThPPID | Name | Peptide Sequence | Length | Functional Classification | Disease | Brand | Company | Physical Appearance | Route of Administartion | Category | Target |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1439 | Th1077 | Urofollitropin | Alpha chain:APDVQDCP Full view | 203 | Ib | Hormonal | BRAVELLE | Ferring Pharmaceuticals Inc. | Sterile, lyophilized powder used after reconstitution with sterile 0.9% Sodium Chloride Injection | Intramuscular and Subcutaneous administration | Fertility Agents | Glutamate carboxypeptidase 2 |
1440 | Th1077 | Urofollitropin | Alpha chain:APDVQDCP Full view | 203 | Ib | Hormonal | Metrodin | N.A. | Sterile, lypholized form contains an acidic, water soluble glycoprotein biologically standardized for FSH gonadotropin activity | Intramuscular injection. | Fertility Agents | Glutamate carboxypeptidase 2 |
1441 | Th1077 | Urofollitropin | Alpha chain:APDVQDCP Full view | 203 | Ib | Hormonal | Fertinex | N.A. | Sterile, lyophilized form contains an acidic, water soluble glycoprotein biologically standardized for FSH gonadotropin activity | Subcutaneous injection. | Fertility Agents | Glutamate carboxypeptidase 2 |
1447 | Th1080 | Choriogonadotropin Alfa | Alpha chain: APDVQDC Full view | 237 | Ib | Hormonal | Choriogonadotropin alfa | Emd serono inc, Ferring pharmaceuticals inc, App pharmaceuticals llc, Bel mar laboratories inc, Bris | N.A. | N.A. | Fertility Agents and Gonadotropins | Integrin alpha-L, Low affinity immunoglobulin gamma Fc region receptor III-B, Complement C1r subcomponent, Complement C1q subcomponent subunit A, Complement C1q subcomponent subunit B, Complement C1q subcomponent subunit C, Low affinity immunoglobulin gamma Fc region receptor III-A, High affinity immunoglobulin gamma Fc receptor I, Low affinity immunoglobulin gamma Fc region receptor II-a, Low affinity immunoglobulin gamma Fc region receptor II-b, Low affinity immunoglobulin gamma Fc region receptor II-c |
1451 | Th1082 | Filgrastim | MTPLGPASSLPQSFLLKCLE Full view | 175 | Ib | Immunological | N.A. | N.A. | N.A. | N.A. | Immunosuppressive Agents, Antineutropenic Agents and Hematopoietic Agents | Lutropin-choriogonadotropic hormone receptor,Follicle-stimulating hormone receptor |
1454 | Th1084 | Becaplermin | SLGSLTIAEPAMIAECKTRT Full view | 109 | Ib | Cardiac | REGRANEX | OMJ Pharmaceuticals, Inc. San German, Puerto Rico | Gel: 0.01 %; clear, colorless to straw-colored gel | External use only | Angiogenesis Inducing Agents | T-cell surface glycoprotein CD1a,Major histocompatibility complex class I-related gene protein,Integrin alpha-L,T-lymphocyte activation antigen CD86,Low affinity immunoglobulin gamma Fc region receptor II-b,T-cell surface glycoprotein CD4,Integrin beta-1,Integrin alpha-V,Integrin beta-3 |
1456 | Th1086 | Interferon Alfa-2B, Recombinant | CDLPQTHSLGSRRTLMLLAQ Full view | 165 | Ib | Immunological | INTRON® A | Merck | Powder or solution | Intramuscular, Subcutaneous, Intralesional, or Intravenous injection | Immunosuppressive Agents | Granulocyte colony-stimulating factor receptor,Neutrophil elastase, Coagulation factor X,Coagulation factor XI,Coagulation factor VII,Coagulation factor VIII,Prothrombin,Prolow-density lipoprotein receptor-related protein 1,Vitamin K-dependent gamma-carboxylase, Platelet-derived growth factor receptor beta,Platelet-derived growth factor receptor alpha,Alpha-2-macroglobulin |
1460 | Th1087 | Oxytocin | CYIQNCPLG Full view | 9 | Ib | Hormonal | Pitocin | JHP Pharmaceuticals | Sterile, clear, colorless aqueous solution of synthetic oxytocin | Intravenous infusion | Oxytocics, Anti-tocolytic Agents and Labor Induction Agents | Interferon alpha/beta receptor 2,Interferon alpha/beta receptor 1, Globotriaosylceramide |
1478 | Th1098 | Exenatide | HGEGTFTSDLSKQMEEEAVR Full view | 39 | Ib | Hormonal/Metabolic | BYETTA | N.A. | N.A. | N.A. | Hypoglycemic Agents | Glucagon-like peptide 1 receptor |
1479 | Th1098 | Exenatide | HGEGTFTSDLSKQMEEEAVR Full view | 39 | Ib | Hormonal/Metabolic | BYDUREON | Amylin Pharmaceuticals | White to off-white powder that is available in a dosage strength of 2 mg exenatide per vial or per pen | N.A. | Hypoglycemic Agents | Glucagon-like peptide 1 receptor |
1480 | Th1099 | Mecasermin | GPETLCGAELVDALQFVCGD Full view | 70 | Ib | Hormonal | N.A. | N.A. | N.A. | N.A. | N.A. | Insulin-like growth factor 1 receptor,Insulin-like growth factor-binding protein 3,Insulin receptor,Cation-independent mannose-6-phosphate receptor |
1520 | Th1107 | Insulin Glulisine | A chain: GIVEQCCTSIC Full view | 51 | Ib | Hormonal/Metabolic | APIDRA | sanofi-aventis | Sterile, aqueous, clear, and colorless solution | N.A. | Antidiabetic Agents | Insulin receptor |
1530 | Th1109 | Nesiritide | SPKMVQGSGCFGRKMDRISS Full view | 32 | Ib | Cardiac | NATRECOR | Scios unit of Johnson & Johnson, | White- to off-white lyophilized powder | Intravenous injection | N.A. | N.A. |
1531 | Th1110 | Thymalfasin | SDAAVDTSSEITTKDLKEKK Full view | 28 | Ib | Infectious/Immunological | Zadaxin | SciClone Pharmaceuticals (SCLN) | N.A. | Subcutaneous injection | N.A. | N.A. |
1532 | Th1111 | Defibrotide | N.A. Full view | 0 | Ib | Immunological | Noravid | sanofi-aventis | N.A. | N.A. | Antithrombins | Adenosine receptor A1,Adenosine receptor A2a,Adenosine receptor A2b |
1535 | Th1114 | Preotact | Parathyroid hormone: Full view | 84 | Ib | Osteological | Preotact | Nycomed | N.A. | Subcutaneous injection | N.A. | Parathyroid hormone/parathyroid hormone-related peptide receptor,Parathyroid hormone 2 receptor |
1556 | Th1120 | Teriparatide | Parathyroid hormone Full view | 34 | Ib | Osteological | Forteo | Eli Lilly and Company | Sterile, colorless, clear, isotonic solution | Subcutaneous injection | Bone Density Conservation Agents | Parathyroid hormone/parathyroid hormone-related peptide receptor |
1576 | Th1124 | Liraglutide | HAEGTFTSDVSSYLEGQAAK Full view | 33 | Ib | Hormonal | Saxenda | Novo Nordisk | Clear, colorless solution | Subcutaneous injection | N.A. | Glucagon-like peptide 1 receptor |
1577 | Th1124 | Liraglutide | HAEGTFTSDVSSYLEGQAAK Full view | 33 | Ib | Hormonal | Victoza | Novo Nordisk | Clear, colorless solution. | Subcutaneous injection | N.A. | Glucagon-like peptide 1 receptor |
1603 | Th1129 | Tesamorelin | YADAIFTNSYRKVLGQLSAR Full view | 44 | Ib | Hormonal | Egrifta | Theratechnologies | Sterile, white to off-white, preservative-free lyophilized powder | Subcutaneous injection | N.A. | Growth hormone-releasing hormone receptor |
1615 | Th1133 | Aflibercept | SDTGRPFVEMYSEIPEIIHM Full view | 431 | Ib | Cancer | Eylea | Regeneron Pharmaceuticals | Sterile, clear, and colorless to pale yellow solution. | Intravitreal injection | Antineoplastic Agents and Ophthalmics | Vascular endothelial growth factor A,Placenta growth factor,Vascular endothelial growth factor B |
1616 | Th1133 | Aflibercept | SDTGRPFVEMYSEIPEIIHM Full view | 431 | Ib | Cancer | Zaltrap | Sanofi and Regeneron Pharmaceuticals, Inc. | Sterile, clear, colorless to pale yellow, non-pyrogenic, preservative-free, solution. | Intravenous infusion | Antineoplastic Agents and Ophthalmics | Vascular endothelial growth factor A,Placenta growth factor,Vascular endothelial growth factor B |
1635 | Th1141 | Epoetin Zeta | APPRLICDSRVLERYLLEAK Full view | 166 | Ib | Cancer | Retacrit | Norbitec | solution for injection | N.A. | N.A. | Erythropoietin receptor |
1638 | Th1144 | Follitropin Alpha | N.A. Full view | 0 | Ib | Adjunct therapy/ Hormonal | Gonal-F | Serono Laboratories | Sterile, lyophilized powder. | Subcutaneous injection | N.A. | N.A. |
1639 | Th1144 | Follitropin Alpha | N.A. Full view | 0 | Ib | Adjunct therapy/ Hormonal | Gonal-f RFF | EMD SERONO | Sterile, lyophilized powde | Subcutaneous injection | N.A. | N.A. |
1640 | Th1145 | Romiplostim | Thrombopoietin recep Full view | 269 | Ib | Immunologcal | Nplate | Amgen | Sterile, preservative-free, lyophilized, solid white powder | Subcutaneous injection | Colony-Stimulating Factors and Thrombopoietic Agents | N.A. |
1641 | Th1146 | Lucinactant | KLLLLKLLLLKLLLLKLLLL Full view | 21 | Ib | Genetic | Surfaxin | Discovery Laboratories, Inc. | Suspension | Intratracheal administration | Pulmonary surfactants | N.A. |
1655 | Th1151 | Somatotropin Recombinant | FPTIPLSRLFDNAMLRAHRL Full view | 192 | Ib | Hormonal/Metabolic | NutropinAQ | Genentech Inc. | Sterile, white lyophilized powder intended for subcutaneous administration after reconstitution with Bacteriostatic Water | Subcutaneous administration | Hormone Replacement Agents | Growth hormone receptor, Prolactin receptor |
1656 | Th1151 | Somatotropin Recombinant | FPTIPLSRLFDNAMLRAHRL Full view | 192 | Ib | Hormonal/Metabolic | BioTropin | Bio-Technology General (Israel) Ltd. | Sterile, white, lyophilized powder | Subcutaneous administration | Hormone Replacement Agents | Growth hormone receptor, Prolactin receptor |
1657 | Th1151 | Somatotropin Recombinant | FPTIPLSRLFDNAMLRAHRL Full view | 192 | Ib | Hormonal/Metabolic | Protropin | Genentech Inc. | Sterile, white, lyophilized powder | Intramuscular or subcutaneous administration | Hormone Replacement Agents | Growth hormone receptor, Prolactin receptor |
1659 | Th1152 | Drotrecogin alfa | Heavy Chain: LIDGKMT Full view | 402 | Ib | Infectious | Xigris | Eli Lilly and Company | Sterile, lyophilized, white to off-white powder | Intravenous Infusion | Antisepsis | Coagulation factor VIII, V, Plasminogen activator inhibitor 1, Thrombomodulin, Vitamin K-dependent protein S, Ceruloplasmin, Prothrombin, Platelet factor 4, Plasma serine protease inhibitor, Serpin B6, Vitamin K-dependent gamma-carboxylase, Endothelial protein C receptor |
1663 | Th1155 | Urokinase | KPSSPPEELKFQCGQKTLRP Full view | 276 | Ib | Haemetological | Kinlytic | N.A. | Sterile lyophilized white powder | Intravenous infusion | N.A. | Plasminogen,Urokinase plasminogen activator surface receptor, Urokinase-type plasminogen activator, Tissue-type plasminogen activator, Plasminogen activator inhibitor 1, 2, Plasma serine protease inhibitor, Low-density lipoprotein receptor-related protein 2, Suppressor of tumorigenicity 14 protein, Nidogen-1 |
1674 | Th1161 | Albiglutide | HGEGTFTSDVSSYLEGQAAK Full view | 645 | Ib | Hormonal disorders | Eperzan | Glaxosmithkline Inc | Powder for Solution | Subcutaneous | Drugs used in diabetes; alimentary tract and metabolism; blood glucose lowering drugs, excl. insulins. | Glucagon-like peptide 1 receptor |
1676 | Th1161 | Albiglutide | HGEGTFTSDVSSYLEGQAAK Full view | 645 | Ib | Hormonal disorders | Tanzeum | Glaxo Smith Kline Llc | Injection, Powder, Lyophilized, for Solution | Subcutaneous | Drugs used in diabetes; alimentary tract and metabolism; blood glucose lowering drugs, excl. insulins. | Glucagon-like peptide 1 receptor |
1682 | Th1163 | Ancestim | NA Full view | 0 | Ib | Cancer | Stemgen | Biovitrum Ab (publ) | NA | Subcutaneous | NA | NA |
1726 | Th1175 | Desirudin | NA Full view | 0 | Ib | Hematological Disorders | Iprivask | Valeant Pharmaceuticals North America LLC | NA | Subcutaneous | NA | NA |
1727 | Th1175 | Desirudin | NA Full view | 0 | Ib | Hematological Disorders | Iprivask | Marathon Pharmaceuticals, LLC | NA | NA | NA | NA |
1729 | Th1176 | Dulaglutide | HGEGTFTSDVSSYLEEQAAK Full view | 275 | Ib | Metabolic Disorders | Trulicity | Eli Lilly and Company | Solution, Injection | Subcutaneous | Hypoglycemic Agents; Drugs Used in Diabetes; Alimentary Tract and Metabolism; Blood Glucose Lowering Drugs, Excl. Insulins | Glucagon-like peptide 1 receptor |
1730 | Th1176 | Dulaglutide | HGEGTFTSDVSSYLEEQAAK Full view | 275 | Ib | Metabolic Disorders | Trulicity | Eli Lilly Canada Inc | Solution | Subcutaneous | Hypoglycemic Agents; Drugs Used in Diabetes; Alimentary Tract and Metabolism; Blood Glucose Lowering Drugs, Excl. Insulins | Glucagon-like peptide 1 receptor |
1756 | Th1182 | Gastric intrinsic factor | NA Full view | 0 | Ib | Hormonal Disorders | Hematogen | Nnodum Pharmaceuticals | NA | NA | NA | NA |
1765 | Th1184 | Human calcitonin | NA Full view | 0 | Ib | Hormonal Disorders | NA | NA | NA | NA | NA | NA |
1780 | Th1188 | Hyaluronidase (Human Recombinant) | NA Full view | 0 | Ib | Adjunct therapy | NA | NA | NA | NA | NA | Hyaluronan; Transforming growth factor beta-1 |
1782 | Th1189 | Idarucizumab | NA Full view | 0 | Ib | Hematological Disorders | Praxbind | Boehringer Ingelheim Pharmaceuticals, Inc. | Injection | Intravenous | Anticoagulant | NA |
1817 | Th1208 | Metreleptin | MVPIQKVQDDTKTLIKTIVT Full view | 147 | Ib | Adjunct therapy | Myalept | Amylin Pharmaceuticals, LLC | Lyophilized Powder for Solution | Subcutaneous | Leptin receptor | |
1818 | Th1209 | Methoxy polyethylene glycol-epoetin beta | NA Full view | 0 | Ib | Hematological Disorders | Mircera | Genentech, Inc. | Solution for Injection | Intravenous | NA | |
1819 | Th1210 | Mepolizumab | NA Full view | 0 | Ib | Respiratory Disorder | Nucala | Glaxosmithkline Inc | Lyophilized Powder | Subcutaneous | Antineoplastic and Immunomodulating Agents, Immunosuppressive Agents, Interleukin Inhibitors | Interleukin-5 |
1824 | Th1215 | Thyroglobulin | MALVLEIFTLLASICWVSAN Full view | 0 | Ib | Hormonal disorders | NA | NA | NA | NA | NA | NA |
1836 | Th1225 | Coagulation factor X human | NA Full view | 0 | Ib | Hematological Disorders | Coagadex | NA | powder and solvent used to make a solution | Intravenous | Blood Coagulation Factors | NA |
1838 | Th1227 | Efmoroctocog alfa | NA Full view | 0 | Ib | Hematological Disorders | ELOCTA | NA | Powder and solvent for solution for injection | Intravenous | Antihemophilic Factor | NA |
1839 | Th1228 | Factor IX Complex (Human) | NA Full view | 0 | Ib | Hematological Disorders | AlphaNine SD or Mononine | Powder and solvent for solution for injection | Intravenous | Antihemophilic agent | NA |